Intermedin and its uses

Details Intermedin and its uses Intermedin and its uses

2005-11-15

2005-11-15

Weber, Jon (Department: 1653)

Chemistry: natural resins or derivatives; peptides or proteins;

Proteins, i.e., more than 100 amino acid residues

C530S324000, C530S326000

Reexamination Certificate

active

06965013

ABSTRACT:
Intermedin nucleic acid compositions and their encoded polypeptides and variants thereof are provided. Intermedin is a novel ligand for the calcitonin receptor-like receptor. In addition to its use as a therapeutic agent, intermedin sequences are utilized in screening and research methods for the determination of specific analogs, agonists, antagonists and mimetics. Intermedin is highly expressed in the intermediate lobe of the pituitary and is shown to stimulate prolactin release by anterior pituitary cells, and to release of growth hormone. Intermedin treatment leads to blood pressure reduction both in normal and hypertensive subjects, as well as the suppression of gastric emptying activity.

REFERENCES:
Roh, J et al., NCBI direct sequence submission accession No. AF529213.
Allen et al., Identification of Two Classes of Prolactin-Releasing Factors in Intermediate Lobe Tumors From Transgenic Mice, Endocrinology, (1995), 136:3093-3099.
Ben-Jonathan et al., Dopamine as a Proclactin (PRL) Inhibitor, Endocr. Rev., (2001), 22(6): 724-763.
Christopoulos et al., Multiple Amylin Receptors Arise From Receptor Activity-Modifying Protein Interaction With the Calcitonin Receptor Gene Product, Mol. Pharmacol., (1999), 56:235-242.
GenBank entry AF529213.
Hay et al., Knockouts and Transgenics Confirm the Importance of Adrenomedullin in the Vasculature, Trends Pharmacol. Sci., (2001), 22:57-59.
Kruger et al., Calcitonin Gene-Related Peptide (CGRP) in the Rat Central Nervous System: Patterns of Immunoreactivity and Receptor Binding Sites, Brain Res., (1988), 463:223-244.
Laudon et al., Prolactin-Releasing Factor: Cellular Origin in the Intermediate Lobe of the Pituitary, Endocrinology, (1990), 126(6):3185-3192.
McLatchie et al., Ramps Regulate the Transport and Ligand Specificity of the Calcitonin-Receptor-Like Receptor, Nature, (1998), 393:333-339.
Meeran et al., Circulating Adrenomedullin does not Regulate Systemic Blood Pressure but Increases Plasma Prolactin After Intravenous Infusion in Humans: A Pharmacokinetic Study, J. Clin. Endocrinol. Metab., (1997), 82(1):95-100.
Mulder et al., Islet Amyloid Polypeptide (Amylin)-Deficient Mice Develop a more Severe From of Alloxan-Induced Diabetes, Am. J. Physiol. Endocrinol. Metab., (2000), 278:E684-E691.
Poyner et al., International Union of Pharmacology. XXXII. The Mammalian Calcitonin Gene-Related Peptides, Adrenomedullin, Amylin, and Calcitonin Receptors, Pharmacol. Rev., (2002), 54(2):233-246.
Salmon et al., Modulation of Morphine Analgesia in α CGRP Mutant Mice, Neuroreport, (1999), 10(4):849-854.
Salmon et al., Altered Neuroadaptation in Opiate Dependence and Neurogenic Inflammatory Nociception in α CGRP—Deficient Mice, Nat. Neurosci., (2001), 4:357-358.
Shindo et al., Vascular Abnormalities and Elevated Blood Pressure in Mice Lacking Adrenomedullin Gene, Circulation, (2001), 104:1964-197.
Zhang et al., Arthritic Calcitonin/α Calcitonin Gene-Related Peptide Knockout Mice have Reduced Nociceptive Hypersensitivity, Pain, (2001), 89:265-273.

Affiliated with

Also associated with

Rating

Intermedin and its uses does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Intermedin and its uses, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Intermedin and its uses will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3484150